MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Apellis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

19.44 -0.41

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.28

Max

19.49

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-56M

-92M

Pardavimai

-46M

167M

Pelno marža

-55.292

Darbuotojai

705

EBITDA

-56M

-80M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+81.02% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-261M

2.3B

Ankstesnė atidarymo kaina

19.85

Ankstesnė uždarymo kaina

19.44

Naujienos nuotaikos

By Acuity

50%

50%

131 / 376 reitingas Healthcare

Apellis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-11 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FCC Approves U.S. Cellular Sale to T-Mobile

2025-07-11 17:28; UTC

Pagrindinės rinkos jėgos

SharpLink Gaming Gains on Ethereum Purchase

2025-07-11 16:57; UTC

Uždarbis

BASF Cuts Outlook on Global Economy Uncertainty

2025-07-12 17:01; UTC

Uždarbis

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

2025-07-12 14:53; UTC

Uždarbis

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

2025-07-12 02:24; UTC

Įsigijimai, susijungimai, perėmimai

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

2025-07-12 02:05; UTC

Įsigijimai, susijungimai, perėmimai

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

2025-07-12 02:05; UTC

Įsigijimai, susijungimai, perėmimai

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

2025-07-12 02:05; UTC

Įsigijimai, susijungimai, perėmimai

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

2025-07-11 21:45; UTC

Rinkos pokalbiai

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

2025-07-11 19:46; UTC

Įsigijimai, susijungimai, perėmimai

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

2025-07-11 19:45; UTC

Rinkos pokalbiai

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

2025-07-11 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

2025-07-11 18:18; UTC

Rinkos pokalbiai

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

2025-07-11 17:35; UTC

Rinkos pokalbiai

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

2025-07-11 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

2025-07-11 16:53; UTC

Rinkos pokalbiai

Crude Futures Add to Early Gains -- Market Talk

2025-07-11 16:42; UTC

Uždarbis

BASF Cuts Outlook on Global Economic Uncertainty

2025-07-11 16:08; UTC

Rinkos pokalbiai

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

2025-07-11 16:05; UTC

Uždarbis

BASF Will Publish Half-Year Results on July 30

2025-07-11 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-11 16:04; UTC

Rinkos pokalbiai

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

2025-07-11 16:03; UTC

Uždarbis

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

2025-07-11 16:02; UTC

Uždarbis

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

2025-07-11 16:01; UTC

Uždarbis

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

2025-07-11 16:00; UTC

Uždarbis

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

2025-07-11 15:59; UTC

Uždarbis

BASF Cuts 2025 Earnings View

2025-07-11 15:58; UTC

Uždarbis

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

2025-07-11 15:57; UTC

Uždarbis

BASF 2Q EBIT Before Special Items EUR810M

2025-07-11 15:54; UTC

Uždarbis

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Akcijų palyginimas

Kainos pokytis

Apellis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

81.02% į viršų

12 mėnesių prognozė

Vidutinis 35.19 USD  81.02%

Aukščiausias 60 USD

Žemiausias 17 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Apellis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

19 ratings

10

Pirkti

9

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

131 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.